Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. on April 24, 2018. The filing discloses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Ann Barbier, M.D. to the Board of Directors as a Class II Director, with a term expiring at the 2019 annual meeting of stockholders. Dr. Barbier brings significant experience in clinical development for rare genetic diseases from her previous roles at Translate Bio, Agios Pharmaceuticals, and Shire.
Compensation and Governance Details
- Stock Option Grant: Dr. Barbier was granted a non-statutory stock option to purchase up to 30,000 shares of common stock. The exercise price is set at the closing price on April 25, 2018, with vesting in equal quarterly installments contingent on continued service.
- Cash Retainer: An annual cash retainer of $35,000 is provided for her service as a non-employee director.
- Indemnification: An indemnification agreement was executed to cover certain expenses, including legal fees and judgments, arising from her service as a director.
Investor Verification Checklist
- Verify the closing stock price on April 25, 2018, to determine the exercise price of the 30,000 share option grant.
- Review the Company's Non-Employee Director Compensation Policy to confirm the standard terms for cash retainers and equity grants.
- Confirm the absence of any undisclosed related-party transactions or conflicts of interest involving Dr. Barbier.
- Check subsequent filings for the impact of this appointment on the Board's composition and committee assignments.